

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/192388 A1

(51) International Patent Classification:

A61K 31/166 (2006.01) *A61K 9/20* (2006.01)
A61K 31/216 (2006.01) *A61P 25/00* (2006.01)
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)
A61K 9/14 (2006.01) *C07C 259/10* (2006.01)

(21) International Application Number:

PCT/US2024/020241

(22) International Filing Date:

15 March 2024 (15.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,626 16 March 2023 (16.03.2023) US

(71) Applicant: **SPRINGWORKS THERAPEUTICS INC.**

[US/US]; 100 Washington Blvd., Stamford, Connecticut
06902 (US).

(72) Inventors: **RUGGIERO, Piero L.**; c/o SpringWorks Therapeutics Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US). **PATTERSON, Kristin**; c/o SpringWorks Therapeutics Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US). **HATCHER, Mark**; c/o SpringWorks Therapeutics Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US). **LIU, Jiping**; c/o SpringWorks Therapeutics Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US). **ILOEJE, Uchenna H**; c/o SpringWorks Therapeutics, Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US). **LANGSETH, Abraham J**; c/o SpringWorks Therapeutics, Inc., 100 Washington Blvd., Stamford, Connecticut 06902 (US).

(74) Agent: **LESSLER, Jay P.**; Blank Rome LLP, 1271 Avenue of the Americas, 15th Floor, New York, New York 10020 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: DOSAGE FORMS OF MIRDAMETINIB




Figure 1

(57) Abstract: The present disclosure relates to an oral dosage form, such as a capsule, comprising (a) mirdametininb having a d90 no more than 250 microns, a d50 no more than 50 microns, or both, and (b) one or more pharmaceutically acceptable excipients. These dosage forms are useful in the treatment of tumors and cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), high grade glioma (HGG), low grade ovarian cancer, Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain. The disclosure also related to improved dosage regimens for mirdametininb treatments.

[Continued on next page]

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))